Skip to content

A prospective, single-center clinical study for the efficacy and safety of CalliSpheres-loaded embolization microspheres loaded with gemcitabine combined with intra-arterial infusion of platinum in the treatment of cervical cancer

A prospective, single-center clinical study for the efficacy and safety of CalliSpheres-loaded embolization microspheres loaded with gemcitabine combined with intra-arterial infusion of platinum in the treatment of cervical cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020030
Enrollment
Unknown
Registered
2018-12-12
Start date
2018-12-12
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Interventions

Sponsors

Lishui Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Understand and sign the informed consent form; 2) Aged 18-75 years old; 3) Cervical cancer is diagnosed by pathology or clinical diagnosis (refer to the 2016 edition of NCCN Clinical Practice Guide - Cervical Cancer); 4) The diameter of lesions in stage Ib and stage IIa is >4cm, stage IIb and above, or radical resection due to inability of patients; 5) Patients with cervical cancer who are newly diagnosed or have uterine bleeding; 6) The expected survival period is more than 3 months; 7) Physical energy ECOG = 1 point.

Exclusion criteria

Exclusion criteria: 1) Those with distant metastasis of the tumor; 2) Those who have suffered or are currently concurrent with other malignancies (except for cured basal or squamous cell skin cancer or cervical carcinoma in situ); 3) a history of major diseases involving the heart, kidney, bone marrow or lung, central nervous system; 4) Those who need antibiotic treatment for recent infections; 5) There are clinical trials participating in other test drugs or devices within four weeks; 6) A comorbidity or social environment that can prevent a subject from following a research plan or even endangering patient safety.

Design outcomes

Primary

MeasureTime frame
PFS;

Secondary

MeasureTime frame
RR;Surgical radical resection rate;1 year recurrence rate;

Countries

China

Contacts

Public ContactJiansong Ji

Lishui Central Hospital

970434943@qq.com+86 13567621225

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026